



Clinical Policy: Lanreotide (Somatuline Depot and Unbranded)

Reference Number: LA.PHAR.391

Effective Date: 04.28.21

Last Review Date: 08.21.24 04.05.24

Line of Business: Medicaid

[Coding Implications](#)
[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Formatted: Underline

****Please note: This policy is for medical benefit****

Formatted: Font color: Auto

Description

Formatted: Underline

Lanreotide (Somatuline[®] Depot) and unbranded lanreotide are a somatostatin analog.

FDA Approved Indication(s)

Somatuline Depot and unbranded lanreotide are indicated for:

- Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy
- Treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival

Somatuline Depot is additionally indicated for:

- Treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana Healthcare Connections that ~~Somatuline Depot~~lanreotide is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Acromegaly (must meet all):

1. Diagnosis of acromegaly as evidenced by one of the following (a or b):
 - a. Pre-treatment insulin-like growth factor-I (IGF-I) level above the upper limit of normal based on age and gender for the reporting laboratory;
 - b. Serum growth hormone (GH) level ≥ 1 $\mu\text{g/mL}$ after a 2-hour oral glucose tolerance test;
2. Prescribed by or in consultation with an endocrinologist;
3. Age ≥ 18 years;
4. Inadequate response to surgical resection or pituitary irradiation (*see Appendix D*), or member is not a candidate for such treatment;
5. Request is for either Somatuline Depot or unbranded lanreotide;

CLINICAL POLICY

Lanreotide



6. Failure of Sandostatin® LAR Depot, unless contraindicated or clinically adverse effects are experienced;

** Prior authorization may be required for Sandostatin LAR Depot*

7. Dose does not exceed 120 mg every 4 weeks.

Approval duration: 6 months

Formatted: Font: Bold

B. Carcinoid Syndrome (must meet all):

1. Diagnosis of carcinoid syndrome (associated with NETs of the gastrointestinal tract, lung, and thymus, otherwise known as carcinoid tumors);
2. Prescribed by or in consultation with an oncologist;
3. Age ≥ 18 years;
4. Request is for either Somatuline Depot or unbranded lanreotide;

5. Failure of Sandostatin® LAR Depot, unless contraindicated, or clinically adverse effects are experienced

** Prior authorization may be required for Sandostatin LAR Depot*

- 5-6. Request meets one of the following (a or b):*

- a. Dose does not exceed 120 mg every 4 weeks;
- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

Formatted: List Paragraph, Numbered + Level: 3 + Numbering Style: 1, 2, 3, ... + Start at: 1 + Alignment: Left + Aligned at: 0.5" + Indent at: 0.75"

Formatted: Font: Bold

C. Neuroendocrine Tumors (must meet all):

1. Diagnosis of one of the following (a, b, or c):
 - a. GEP-NET (*see Appendix D for tumor types*), and:
 - i. If insulinoma, disease is somatostatin receptor (SSTR)-positive;
 - b. Pheochromocytoma or paraganglioma (adrenal NETs);
 - c. One of the following NETs which is SSTR-positive or has hormonal symptoms (i, ii, or iii):
 - i. Thymic NET;
 - ii. Bronchopulmonary NET;
 - iii. Grade 3 NET with favorable biology (i.e., relatively low Ki-67 [$< 55\%$] slow growing, or SSTR-positive based PET imaging);

2. Prescribed by or in consultation with an oncologist;

3. Age ≥ 18 years;

4. Request is for either Somatuline Depot or unbranded lanreotide;

5. Failure of Sandostatin® LAR Depot, unless contraindicated or clinically adverse effects are experienced;

** Prior authorization may be required for Sandostatin LAR Depot*

6. Request meets one of the following (a or b):*

- a. Dose does not exceed 120 mg every 4 weeks;
- b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 6 months

Formatted: Font: 10 pt, Italic

Formatted: Font: Bold

D. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

II. Continued Therapy

A. Acromegaly (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy (*see Appendix D*);
3. If request is for a dose increase, new dose does not exceed 120 mg every 4 weeks.

Approval duration: 12 months

Formatted: Font: Bold

B. Carcinoid Syndrome and Neuroendocrine Tumors (must meet all):

1. Currently receiving medication via Louisiana Healthcare Connections benefit, or documentation supports that member is currently receiving Somatuline Depot for a covered indication and has received this medication for at least 30 days;
2. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 120 mg every 4 weeks;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration: 12 months

Formatted: Font: Bold

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

Formatted: Font color: Text 1

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – LA.PMN.53 for Medicaid or evidence of coverage documents.

Formatted: List Paragraph, Indent: Left: 1"

A.

Formatted: Normal, No bullets or numbering

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration
GEP: gastroenteropancreatic
GH: growth hormone

IGF-I: insulin-like growth factor
NET: neuroendocrine tumor
SSTR: somatostatin receptor

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Octreotide acetate (Sandostatin LAR deport) (IM)	<u>Acromegaly:</u> 20-40 mg IM every 4 weeks	See dosing regimen
	<u>Carcinoid tumors:</u> 20-30 mg IM every 4 weeks	
	<u>Neuroendocrine Tumors:</u> 20-30 mg IM every 4 weeks	

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): hypersensitivity to lanreotide
- Boxed warning(s): none reported

Appendix D: General Information

- Response to acromegaly therapy (e.g., somatostatin analogs, surgical resection, pituitary irradiation) may include:
 - Improved GH or IGF-I serum concentrations
 - Improved tumor mass control
- NCCN guidelines - Neuroendocrine and Adrenal Tumors
 - GEP-NETs
 - Gastrointestinal tract tumors include the appendix, stomach, colon and rectum, duodenum, gastric, jejunum and ileum.
 - Pancreatic tumors include insulinoma, gastrinoma, VIPoma (vasoactive intestinal polypeptide), glucagonoma, and nonfunctioning pancreatic tumors.
 - For patients with insulinoma, lanreotide should be considered only if the tumor expresses SSTR.
 - Patients experiencing disease progression on lanreotide should continue treatment with lanreotide if the tumor is functional. Lanreotide may be used in combination with other systemic therapy options.



V. Dosage and Administration*

CLINICAL POLICY

Lanreotide



Indication	Dosing Regimen	Maximum Dose
Acromegaly	<u>Initial:</u> 90 mg SC every 4 weeks for 3 months <u>Maintenance:</u> 90 to 120 mg SC every 4 weeks Dose should be adjusted according to reduction in serum GH or IGF-1 levels and/or changes in symptoms.	Maintenance: 120 mg every 4 weeks
GEP-NETs, carcinoid syndrome	120 mg SC every 4 weeks If patients are being treated with Somatuline Depot for both GEP-NET and carcinoid syndrome, do not administer an additional dose	120 mg every 4 weeks

**Intended for administration by a healthcare provider*

VI. Product Availability

Single-dose prefilled syringes: 60 mg/0.2 mL, 90 mg/0.3 mL, 120 mg/0.5 mL

VII. References

1. Somatuline Depot Prescribing Information. Signes, France: Ipsen Pharma Biotech; February 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022074s0261bl.pdf. Accessed August 4, 2023.
2. Lanreotide Prescribing Information. Warren, NJ: Cipla USA, Inc.; December 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215395s0001bl.pdf. Accessed August 17, 2023.
3. Melmed S, Bronstein MD, Chanson P. A Consensus Statement on acromegaly therapeutic outcomes. *Nat Rev Endocrinol*. 2018 Sep;14(9):552-561. doi: 10.1038/s41574-018-0058-5.
4. Katznelson L, Laws Jr. ER, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab*. 2014;99:3933-3951.
5. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed August 4, 2023.
6. National Comprehensive Cancer Network. Neuroendocrine and Adrenal Tumors Version 1.2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed August 4, 2023.
7. Fleseriu M, Biller BMK, Freda PU, et al. A Pituitary Society update to acromegaly management guidelines. *Pituitary*. 2021; 24: 1-13.
8. Guistina A, Barkhoudarian G, Beckers A, et al. Multidisciplinary management of acromegaly: A consensus. *Rev Endocr Metab Disord*. 2020; 21(4): 667-678.

Coding Implications

CLINICAL POLICY

Lanreotide

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1930	Injection, lanreotide, 1 mg
J1932	Injection, lanreotide, (cipl), 1 mg
C9399	Unclassified drugs or biologicals

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Policy created	01.21	04.28.21
For acromegaly, added confirmatory diagnostic requirements (IGF-I or GH) per PS/ES practice guidelines; per NCCN, specified that thymic/ bronchopulmonary NETs and insulinomas must be SSTR-positive or have hormonal symptoms and added that any grade 3 NETs with favorable biology are also coverable. Template changes applied to other diagnoses/indications and continued therapy section. References reviewed and updated. Added redirection to Sandostatin LAR depot.	06.25.23	10.05.23
Annual review; Added unbranded lanreotide acetate formulation; updated neuroendocrine tumor criteria Grade 3 NET examples and pancreatic tumor examples in Appendix D to align with current NCCN Neuroendocrine Tumors for the Gastrointestinal Tract, Lung, and Thymus guideline and NCCN compendium; references reviewed and updated.	04.05.24	<u>07.10.24</u>
<u>For carcinoid syndrome, added redirection to Sandostatin LAR depot, which mirrors other indications. Added statement that policy is for Medical Benefit.</u>	<u>08.21.24</u>	

Formatted Table

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program

CLINICAL POLICY

Lanreotide

approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2024 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any

Formatted: Don't adjust space between Latin and Asian text, Don't adjust space between Asian text and numbers



CLINICAL POLICY

Lanreotide

means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.